RIGEL PHARMACEUTICALS INC

Rigel Pharmaceuticals is a biotechnology company that develops and commercializes novel therapies targeting signaling pathways implicated in hematologic disorders and cancer. The company sells three FDA-approved products: TAVALISSE, an oral spleen tyrosine kinase inhibitor for chronic immune thrombocytopenia; REZLIDHIA, an IDH1 inhibitor for relapsed or refractory acute myeloid leukemia; and GAVRETO, a RET kinase inhibitor for RET fusion-positive cancers. Rigel operates an integrated commercial organization focused on hematologists and hematologist-oncologists in the United States, while leveraging partnerships with established pharmaceutical companies for international distribution. The company generates revenue through direct product sales, collaboration revenues, and milestone or royalty payments from strategic partnerships and sublicense agreements.